{'fraction_non_alphanumeric': 0.01996007984031936, 'fraction_numerical': 0.021956087824351298, 'mean_word_length': 5.078787878787879, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Research contributions to combination chemotherapy.

Beginning with my appointment at the Clinical Center of the National Cancer Institute in 1955, I have devoted my major research work to investigation of patients with acute leukemia. During the first ten-year period (1955-1965) I was responsible for an acute leukemia service, where 477 patients with acute leukemia were studied and received definitive therapy. In 1965, I moved to the University of Texas M. D. Anderson Hospital and Tumor Institute at Houston as chief of research hematology, where I have continued clinical research, particularly in adults with acute leukemia. To date, more than 500 additional patients have been studied and treated. As a participant in the first cooperative clinical trial in acute leukemia, I had a role in developing the first clinical study demonstrating that the antileukemic activity of a drug can be detected and evaluated quantitatively, by its ability to prolong the duration of remission, when given to